EyePoint Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EYPT research report →
Range $0.5 – $40
Price Chart
About the company
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom.
- CEO
- Jay S. Duker
- IPO
- 2005
- Employees
- 214
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on EYPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.65M
- P/E
- -0.07
- PEG
- 0.00
- P/S
- 13.05
- P/B
- 0.24
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
- Gross Margin
- 44.71%
- Op Margin
- -13642.03%
- Net Margin
- -13281.23%
- ROE
- -168.83%
- ROIC
- -275.55%
Latest fiscal year · YoY change
- Revenue
- $31.37M-27.5%
- Gross Profit
- $29.30M-25.9%
- Op Income
- $-243,434,000
- Net Income
- $-231,962,000-77.2%
- EPS
- $-3.17-36.6%
- OCF Growth
- -90.2%
- FCF Growth
- -86.8%
- 52W High
- $19.11
- 52W Low
- $0.23
- 50D MA
- $2.00
- 200D MA
- $9.97
- Beta
- 1.85
- RSI (14)
- 17
- Avg Volume
- 8.43M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
EyePoint said wet AMD failed in Phase III, but management is shifting fully to DME and remains confident DURAVYU can still be successful there.· November 12, 2026
- Two Phase III wet AMD trials missed the primary endpoint in the full analysis population, prompting EyePoint to discontinue the wet AMD program and cut about 53% of the workforce.
- Management said DURAVYU still showed biological activity, vision improvement, better treatment-burden reduction, OCT-based anatomic control, and a favorable safety profile in wet AMD.
- Focus has now moved to DME, where management cited distinct disease biology, prior VERONA Phase II data, and a rationale that DURAVYU may work differently than in wet AMD.
- Cash was about $118 million at September 30, 2026, and management said runway should last into late Q3 2027, though they are evaluating additional cost savings and business development.
- COMO and CAPRI top-line results are expected early in the fourth quarter of 2027, and management plans to report both trials simultaneously.
EyePoint did not report full P&L figures on the call, but it did say third quarter 2026 results were issued in the morning press release. The company ended September 30, 2026 with approximately $118 million in cash, cash equivalents, investments and marketable securities. Management said the workforce reduction of about 53% will generate $30 million in annualized savings once fully implemented. The company expects its current runway to fund operations into late Q3 2027, excluding any potential business-development or financing proceeds and other operational savings under review. On strategy, management said wet AMD development is being discontinued and the company is now focused on DME; top-line COMO and CAPRI results are expected early in Q4 2027.
Jay Duker struck a disappointed but determined tone, saying the wet AMD primary endpoint misses were deeply disappointing, but that the studies still showed DURAVYU has biologic activity and a favorable safety and durability profile. He argued DME is biologically distinct from wet AMD and cited IL-6 biology, prior VERONA data, and the need for fewer injections as reasons DURAVYU may perform better in DME. He repeatedly emphasized that the company is now focused on maximizing value through DME execution while still reviewing whether there is any path back to wet AMD based on subgroup or biomarker findings.
George Elston focused on capital discipline and cost reduction. He said cash, cash equivalents, investments and marketable securities were approximately $118 million at September 30, 2026, and that the company expects runway into late Q3 2027, subject to potential business development, financing, or additional operating actions. He highlighted the roughly 53% workforce reduction and said it should deliver $30 million in annualized savings once fully implemented. He also said management is actively reviewing further levers to extend runway and preserve flexibility while prioritizing COMO and CAPRI.
Analysts pressed management on DME trial variability, futility analysis, rescue criteria, and whether the company may need more capital before the DME readout. Management said COMO and CAPRI are sufficiently powered, no futility analysis is planned, and the updated rescue threshold from a 10-letter decline plus 50-micron CST increase to a greater than 5-letter decline plus 50-micron CST increase was intended to help preserve the BCVA endpoint. On capital, George said the company 'just about get[s] there' with current resources but is actively evaluating additional cash-conservation measures, while Jay said the goal is not to run out of cash before DME data next year.
Management believes DME is a better biological and commercial fit for DURAVYU than wet AMD, and it cited VERONA, safety experience in about 450 wet AMD patients, and the possibility of stronger uptake in a disease with high treatment burden and high discontinuation rates. The updated DME protocol and management’s confidence that the studies are adequately powered suggest they are actively trying to improve the odds of success. The company also left open the possibility of further business development or even a future wet AMD path if subgroup data identify a clear opportunity.
The obvious risk is that the company just failed two Phase III wet AMD trials on the primary endpoint, forcing a program shutdown and a major workforce reduction. Cash is tight relative to the timing of the DME readout, with runway only into late Q3 2027 while top-line DME data are expected in Q4 2027, so additional capital or further cuts may still be needed. There is also no guarantee the DME biology will translate, and management itself said any future wet AMD retry would require identifying a clear subgroup or biomarker signal before a new trial could be designed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.8%
- Shares Outstanding
- 113.78M
- Float Shares
- 97.67M
of shares held by institutions
209 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Montanova Capital, LLC | 8.30M | 0 |
| Blackrock, Inc. | 7.98M | ▲ 518.97K |
| Cormorant Asset Management, LP | 7.00M | ▼ 1.26M |
| Federated Hermes, Inc. | 6.93M | ▲ 1.25M |
| Adage Capital Partners Gp, L.L.C. | 4.83M | ▲ 1.53M |
| Vanguard Group Inc | 4.82M | ▲ 1.03M |
| Commodore Capital LP | 4.60M | ▲ 1.77M |
| Franklin Templeton Inc | 4.46M | ▼ 349.41K |
| Jupiter Topco LLC | 3.77M | ▲ 3.77M |
| Vanguard Capital Management LLC | 3.67M | ▲ 38.12K |
| Janus Henderson Group Ltd. | 3.60M | ▲ 663.44K |
| Aberdeen Group PLC | 3.05M | ▲ 1.05M |
Held by 209 ETFs
Biggest fund positions in EYPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 20, 26 | Elston George | other | 5,000 |
| Aug 20, 26 | Elston George | other | 64,953 |
| Aug 20, 26 | Elston George | other | 64,953 |
| Aug 20, 26 | Elston George | other | 5,000 |
| Aug 18, 26 | Zaderej Karen L. | buy | 10,600 |
| Jul 10, 26 | Duker Jay S. | other | 16,667 |
| Jul 10, 26 | Duker Jay S. | other | 8,059 |
| Jul 10, 26 | Duker Jay S. | other | 16,667 |
| Jun 30, 26 | Ribeiro Ramiro | other | 2,437 |
| Jun 30, 26 | Ribeiro Ramiro | other | 2,438 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EYPT coverage
Recent articles, reports, and earnings notes.
No research on EYPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EYPT report →ROSEN, GLOBAL INVESTOR COUNSEL, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPT
newsfilecorp.com · Nov 20
EyePoint, Inc. (NASDAQ: EYPT) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in EyePoint, Inc. Securities Lawsuit – Contact Portnoy Law Firm
globenewswire.com · Nov 20
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against EyePoint, Inc. (EYPT) - Investors Who Suffered Losses Are Encouraged to Contact the Firm
newsfilecorp.com · Nov 20
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPT
globenewswire.com · Nov 19
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against EyePoint, Inc. (NASDAQ: EYPT) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
globenewswire.com · Nov 19
EYPT Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against EyePoint, Inc.
prnewswire.com · Nov 19
Pomerantz Law Firm Announces the Filing of a Class Action Against EyePoint, Inc. and Certain Officers - EYPT
prnewswire.com · Nov 19
Faruqi & Faruqi, LLP Urges EyePoint, Inc. (EYPT) Investors to Seek Counsel Before the January 19, 2027 Lead Plaintiff Deadline in the Securities Class Action
newsfilecorp.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.